t2307

Icotinib Hydrochloride (BPI-2009H) is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.

T-2307, a broad-spectrum arylamidine compound, demonstrates potent antifungal properties both in vitro and in vivo. Its activity extends to clinically significant pathogens such as Candida species (MIC range: 0.00025 to 0.0078 μg/ml), Cryptococcus neoformans (MIC range: 0.0039 to 0.0625 μg/ml), and Aspergillus species (MIC range: 0.0156 to 4 μg/mL).